Zane Ellen M, a director at Boston Scientific, sold 12,891 shares, indicating potential insights into the company's future prospects.The FARAPULSE system's sales surged by 63% in Q3 2025, with expectations of significant market penetration for Pulsed Field Ablation (PFA) technology.Boston Scientific's financial health is strong, with a P/E ratio of approximately 52.64 and a moderate debt-to-equity ratio of about 0.54.Boston Scientific Corporation (NYSE: BSX) is a leading medical device company known for its ...